PH12021551398A1 - Fusion protein constructs for complement associated disease - Google Patents

Fusion protein constructs for complement associated disease

Info

Publication number
PH12021551398A1
PH12021551398A1 PH1/2021/551398A PH12021551398A PH12021551398A1 PH 12021551398 A1 PH12021551398 A1 PH 12021551398A1 PH 12021551398 A PH12021551398 A PH 12021551398A PH 12021551398 A1 PH12021551398 A1 PH 12021551398A1
Authority
PH
Philippines
Prior art keywords
fusion protein
protein constructs
complement
associated disease
complement associated
Prior art date
Application number
PH1/2021/551398A
Other languages
English (en)
Inventor
Justin Andrew Caravella
Michael Steven Curtis
Kelly C Fahnoe
Vernon Michael Holers
Cheng Ran Huang
Susan L Kalled
Ellen Garber Stark
Michael Storek
Frederick Robbins Taylor
Shelia Marie Violette
Original Assignee
Q32 Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q32 Bio Inc filed Critical Q32 Bio Inc
Publication of PH12021551398A1 publication Critical patent/PH12021551398A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PH1/2021/551398A 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease PH12021551398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Publications (1)

Publication Number Publication Date
PH12021551398A1 true PH12021551398A1 (en) 2022-11-07

Family

ID=71076704

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/551398A PH12021551398A1 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Country Status (13)

Country Link
US (1) US20240301043A1 (https=)
EP (1) EP3893916A4 (https=)
JP (3) JP7444886B2 (https=)
KR (2) KR102762828B1 (https=)
CN (1) CN113660944A (https=)
AU (2) AU2019398214C1 (https=)
IL (1) IL283841A (https=)
MA (1) MA54468A (https=)
MX (1) MX2021006930A (https=)
MY (1) MY209796A (https=)
PH (1) PH12021551398A1 (https=)
SG (1) SG11202106073QA (https=)
WO (1) WO2020123662A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
CA3141778A1 (en) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN117624347A (zh) * 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
EP4617287A1 (en) * 2022-11-10 2025-09-17 Longbio Pharma (Suzhou) Co., Ltd. Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
US7708999B2 (en) * 2001-12-28 2010-05-04 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9815890B2 (en) * 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
AU2011336702B2 (en) 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
AU2014209350B8 (en) * 2013-01-23 2019-04-18 Department Of Veterans Affairs (Us) Targeting constructs based on natural antibodies and uses thereof
AU2014348683B2 (en) * 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10035848B2 (en) 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
ES2865825T3 (es) * 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
CN106687123A (zh) * 2014-06-05 2017-05-17 科罗拉多州大学评议会 Map44多肽和基于天然抗体的构建体及其用途
CR20170383A (es) * 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123

Also Published As

Publication number Publication date
JP2024059791A (ja) 2024-05-01
KR102762828B1 (ko) 2025-02-05
KR20210148076A (ko) 2021-12-07
AU2019398214C1 (en) 2024-03-28
IL283841A (en) 2021-07-29
AU2024201109A1 (en) 2024-03-14
US20240301043A1 (en) 2024-09-12
CN113660944A (zh) 2021-11-16
MY209796A (en) 2025-08-05
CA3123004A1 (en) 2020-06-18
MA54468A (fr) 2022-04-13
KR20250021629A (ko) 2025-02-13
SG11202106073QA (en) 2021-07-29
EP3893916A2 (en) 2021-10-20
EP3893916A4 (en) 2023-03-29
WO2020123662A2 (en) 2020-06-18
JP2022512234A (ja) 2022-02-02
JP7444886B2 (ja) 2024-03-06
MX2021006930A (es) 2021-11-17
WO2020123662A3 (en) 2020-07-23
AU2019398214B2 (en) 2023-11-23
AU2019398214A1 (en) 2021-07-01
JP7811315B2 (ja) 2026-02-05
JP2026053563A (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
MY209796A (en) Fusion protein constructs for complement associated disease
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
IL280467A (en) Antibody constructs for cldn18.2 and cd3
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
NZ782442A (en) Antibodies that bind cd39 and uses thereof
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2020000960A (es) Anticuerpos anti-tigit.
EP4374922A3 (en) Anti-c5 antibodies and uses thereof
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
AR105267A1 (es) Anticuerpos de unión a tau
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2024004299A (es) Anticuerpos anti-pmel17 y conjugados de los mismos.
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof